Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$71.3MBeat by $3.6M
EPS-$0.73Beat by $0.08
Revenue estimate$67.7M
EPS estimate-$0.81
“The demand we are seeing from both patients and physicians reinforces the significant unmet need in acquired HO and the opportunity for IMCIVREE to transform the treatment paradigm for this devastating disease.”
David Meeker

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$84.5M
EPS estimate-$0.72

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$6.75B+5.7%
Enterprise value$6.8B+6.9%
P/S31.1×-9.8×

FAQ

When did Rhythm Pharmaceuticals, Inc. report Q2 2026 earnings?
Rhythm Pharmaceuticals, Inc. (RYTM) reported Q2 2026 earnings on August 4, 2026 before market open.
What were Rhythm Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
Rhythm Pharmaceuticals, Inc. reported revenue of $71.3M and eps of $-0.73 for Q2 2026.
Did Rhythm Pharmaceuticals, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $67.7M by $3.6M. EPS beat the consensus estimate of $-0.81 by $0.08.
How did Rhythm Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 46.9% from $48.5M a year earlier and eps grew 2.7% from $-0.75.
Where can I find Rhythm Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-052170) and the 10-Q periodic report (0001628280-26-052533) directly on SEC EDGAR. The filing index links above go to sec.gov.